EP Patent

EP1254911A1 — Monocyclic L-nucleosides, analogs and uses thereof

Assigned to Bausch Health Americas Inc · Expires 2002-11-06 · 24y expired

What this patent protects

Novel monocyclic L- nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments…

USPTO Abstract

Novel monocyclic L- nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th 1 and Th 2 response.

Drugs covered by this patent

Patent Metadata

Patent number
EP1254911A1
Jurisdiction
EP
Classification
—
Expires
2002-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Bausch Health Americas Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.